The COVID-19 pandemic has had, and continues to have, major impacts on planned and ongoing clinical trials. Its effect on trial data creates multiple potential statistical issues. The scale of impact is unprecedented, but when viewed individually, many of the issues are well defined and feasible to address.
In a previous event in the DIA DIRECT COVID-19 Webinar Series, a team comprised of 18 industry statisticians gave a comprehensive overview of their recommendations to address COVID-19 statistical issues. Join us in this event to explore aspects of the team's recommendations in more depth:
- The use of the estimand framework to assess and address pandemic-related disruptions;
- Analysis strategies for pandemic-related missing and unobservable values.
- R. Daniel Meyer, (Moderator) Head of Statistics, Rare Disease, Pfizer, Inc.
- Robert Hemmings (Opening Remarks), Partner, Consilium Salmonson, and Hemmings; Formerly MHRA, UK; Co-opted Member, CHMP,EMA; Chair, SAWP, EMA
- Xin Li, Global Head of Biostatistics I2ON, Roche/Genentech
- Bohdana Ratitch, Principal Statistician, Bayer Inc
- David Wright, Head of Statistical Innovation, AstraZeneca